PARIS – Selective tyrosine kinase 2 inhibitor reached a 75% PASI 75 response rate in moderate to severe psoriasis at 12 weeks.
Type 2 diabetes risk was significantly higher among patients with psoriatic arthritis, even when compared with patients with psoriasis alone.
Without biosimilar gap discounts in 2017, beneficiaries would have paid nearly $1,700 more in projected out-of-pocket costs for infliximab-dyyb...
Adherence to daily topical psoriasis treatment improved significantly among patients who used a reminder app.
Two phase 3 trials suggested that risankizumab can do more to improve quality of life, with similar safety.
Infliximab was associated with a statistically significant increased risk of serious infection, compared with non-biologic systemic treatments.
Clinical Topics & News
Latex allergies are most commonly seen in those exposed to rubber gloves; however, psoriasis patients may experience allergic responses to latex...
An allergic reaction provoked by reexposure to an allergen or antigen is known as a type I or immediate hypersensitivity reaction. Latex allergy...
Inflammatory linear verrucous epidermal nevus (ILVEN) is a rare cutaneous disease that presents as linear psoriasiform plaques with associated...
CHICAGO – “The IL-23 blockers are ideal for patients who want a few injections.”